Educational Opportunities

This course includes: 

• Video presentation by a leading expert
• Pre- and post-exams to measure your understanding
• CME and MOC claiming online

Desmond Schatz, MD 

Desmond Schatz, MD, is Professor and Interim Chairman of Pediatrics, Medical Director of the Diabetes Institute and Director of the Clinical Research Center within the CTSI at the University of Florida, Gainesville. He served as President of Science and Medicine of the American Diabetes Association in 2016. Dr. Schatz has been involved in Type 1 diabetes research since the mid 1980’s and has published over 360 manuscripts, the majority related to the prediction, natural history, genetics, immunopathogenesis and prevention of the disease, as well as the management of children and adolescents with Type 1 diabetes. He is the Principal Investigator (PI) on several NIH awards. He is the PI of the University of Florida Clinical Center participating in the NIH-funded TrialNet (a founding member of the DPT-1 in 1994). He is co-PI on a Program Project Grant seeking to understand the immunopathogenesis of Type 1 diabetes, and also serve as PI for the NIH-funded international newborn genetic screening (TEDDY) program in North Central Florida. He is the PI on the NIH-funded Human Islet Research Network (HIRN) Grant evaluating novel markers and mechanisms of beta cell destruction. He is the PI of the University of Florida site participating in the Type 1 Diabetes Exchange. Dr. Schatz has served in numerous capacities (Committees, Study Sections) for the American Diabetes Association, JDRF and NIH. He serves on the external advisory board for the NIH- and CDC-funded SEARCH and TODAY studies in youth with Type 2 diabetes and on the JDRF-funded Australian INIT II studies. He was awarded the Mary Tyler Moore and S Robert Levine JDRF Excellence in Clinical Research Award, the 2009 Cure Award from the American Diabetes Association, the 2010 Public Policy Leadership Award, the prestigious Banting Medal and the ISPAD Prize for achievement. 

LEARNING OBJECTIVES

Upon completion of this activity, learners will be able to:

• Define endotypes and need to identify heterogeneity of type 1 diabetes
• Discuss important effect of age in disease process
• Describe efforts aimed at interdicting type 1 diabetes now and in the future

MAINTENANCE OF CERTIFICATION

Successful completion of this CME activity enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points. 

Your participation information will be shared with the ACCME, which will in turn report your points to ABIM. Successful completion of a course examination is required to earn ABIM MOC points.

ACCREDITATION AND DESIGNATION STATEMENTS

The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American College of Endocrinology designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.